- Record: found
- Abstract: found
- Article: not found
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
Joel Kremer ,
Zhan-Guo Li ,
Stephen Hall ,
Roy Fleischmann ,
Mark Genovese ,
Emilio Martin-Mola ,
John D Isaacs ,
David Gruben ,
Gene Wallenstein ,
Sriram Krishnaswami ,
Samuel H Zwillich ,
Tamas Koncz ,
Richard Riese ,
John Bradley
Aug 20 2013
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Many patients with rheumatoid arthritis (RA) do not achieve adequate and safe responses with disease-modifying antirheumatic drugs (DMARDs). Tofacitinib is a novel, oral, Janus kinase inhibitor that treats RA.